Free Trial

CRISPR Therapeutics (CRSP) Stock Price, News & Analysis

-0.75 (-1.33%)
(As of 05/20/2024 ET)
Today's Range
50-Day Range
52-Week Range
931,528 shs
Average Volume
1.74 million shs
Market Capitalization
$4.71 billion
P/E Ratio
Dividend Yield
Price Target

CRISPR Therapeutics MarketRank™ Stock Analysis

Analyst Rating
2.35 Rating Score
33.3% Upside
$73.93 Price Target
Short Interest
17.18% of Shares Sold Short
Dividend Strength
News Sentiment
0.27mentions of CRISPR Therapeutics in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$3.87 M Sold Last Quarter
Proj. Earnings Growth
From ($5.64) to ($4.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.97 out of 5 stars

Medical Sector

362nd out of 917 stocks

Biological Products, Except Diagnostic Industry

53rd out of 149 stocks

CRSP stock logo

About CRISPR Therapeutics Stock (NASDAQ:CRSP)

CRISPR Therapeutics AG is a leading biotechnology company specializing in developing transformative gene-editing therapies. Founded in 2013, the company has quickly emerged as a key player in precision medicine, leveraging the power of CRISPR-Cas9 technology to address a wide range of genetic diseases.

CRISPR Therapeutics aims to develop innovative therapies that harness the potential of gene editing to provide life-changing treatments for patients in need. The company seeks to correct disease-causing mutations at the root level by precisely modifying genes and promising long-lasting and potentially curative therapies.

Headquartered in Zug, Switzerland, with additional offices in the United States, CRISPR Therapeutics operates globally to advance its groundbreaking research and collaborate with partners in the scientific and medical communities. The company's multidisciplinary team of scientists, researchers, and industry experts is dedicated to pushing the boundaries of genetic medicine and revolutionizing patient care.

CRISPR Therapeutics focuses on developing CRISPR-Cas9-based therapies that target specific genetic sequences. The company's pipeline includes a diverse portfolio of investigational treatments for various diseases, including blood disorders, cancer, and rare genetic conditions. The company's lead product candidate, CTX001, aims to treat transfusion-dependent beta-thalassemia and sickle cell disease by editing patients' hematopoietic stem cells. This product candidate has received Orphan Drug Designation from the U.S. FDA and has been designated with Fast Track Designation from the FDA. 

The target market for CRISPR Therapeutics' gene-editing therapies primarily comprises patients suffering from genetic diseases with limited treatment options. The company's focus on hematopoietic stem cells and blood disorders demonstrates its commitment to addressing this field's unmet medical needs. By targeting genetic mutations directly, CRISPR Therapeutics aims to provide personalized and potentially curative treatments for individuals affected by these conditions.

CRISPR Therapeutics boasts a seasoned management team that combines diverse expertise in genetics, drug development, and business strategy. Led by Chief Executive Officer Samarth Kulkarni, Ph.D., the management team has a proven track record of success in the biotech industry. The company's leadership is dedicated to driving scientific innovation, clinical progress, and commercial growth.

Over the past few years, CRISPR Therapeutics has demonstrated mixed financial performance, driven by its groundbreaking research, development efforts and slowed market uncertainty. The company has struggled with reporting revenue growth, reflecting uncertainty in the interest and investment in gene-editing technologies. 

CRISPR Therapeutics' valuation metrics, such as its price-to-earnings and price-to-book ratios, are competitive compared to its industry peers. Investors recognize the potential of CRISPR Therapeutics' gene-editing therapies to revolutionize the treatment of genetic diseases, leading to increased investor sentiment and a positive outlook for the company's stock. 

CRISPR Therapeutics stock has exhibited mixed performance in recent years. The company's shares have experienced significant price movements, reflecting the market's recognition of its innovative approach to gene editing. However, there have been several declines in the stock price due to missed earnings reports and regulatory concerns. 

CRISPR Therapeutics operates within the broader biotechnology industry, which is experiencing rapid advancements and substantial growth potential. The field of gene editing has garnered significant attention due to its ability to target and potentially cure genetic diseases. The industry's growth is fueled by increasing investments in research and development and a growing understanding of the human genome.

Competition within the industry is intense, with several companies vying to develop gene-editing therapies. However, CRISPR Therapeutics has established itself as a leader in the space thanks to its pioneering CRISPR-Cas9 technology and its robust pipeline of product candidates. The company's early clinical trial success and strategic partnerships further strengthen its competitive positioning.

Regulatory and political factors also play a crucial role in shaping the industry. Gene editing is a rapidly evolving field, and regulatory frameworks are being developed to ensure these technologies' ethical and safe application. Changes in regulations or public sentiment regarding gene editing could impact the industry's trajectory and the adoption of gene therapies.

CRISPR Therapeutics has several avenues for growth and expansion. One significant opportunity lies in the advancement of its pipeline and the successful commercialization of its gene-editing therapies. As the company progresses through clinical trials and obtains regulatory approvals, it can potentially bring life-changing treatments to patients worldwide.

While CRISPR Therapeutics has demonstrated significant progress and potential, it is essential to acknowledge the risks and challenges inherent in the biotechnology industry. The company faces scientific, regulatory, and commercialization risks that could impact its future prospects.

Scientific challenges include ensuring the efficacy and safety of gene-editing therapies and addressing potential off-target effects. The complex nature of genetic diseases and the need for long-term follow-up data pose additional hurdles in demonstrating the durability and efficacy of treatments.

Regulatory uncertainties and evolving guidelines can impact the timeline and cost of clinical development and regulatory approval. Changes in regulations or unexpected regulatory hurdles may delay the commercialization of CRISPR Therapeutics' products and hinder market access.

Commercialization challenges include pricing and reimbursement considerations and competition from other companies developing gene therapies. The ability to secure favorable reimbursement terms and navigate complex healthcare systems will be crucial for successfully commercializing CRISPR Therapeutics' therapies.

CRISPR Therapeutics has implemented robust risk management strategies to mitigate these risks and challenges. The company strongly focuses on rigorous scientific research and clinical development, ensuring thorough evaluation of its therapies before advancing them into clinical trials. CRISPR Therapeutics aims to address scientific risks associated with gene editing by prioritizing patient safety and efficacy.

Additionally, CRISPR Therapeutics actively engages with regulatory authorities to stay informed about evolving guidelines and requirements. The company invests in regulatory affairs expertise to navigate the complex regulatory landscape effectively. CRISPR Therapeutics aims to minimize regulatory risks and ensure a smooth path to market approval by proactively collaborating with regulatory agencies and adhering to stringent compliance standards.

CRSP Stock Price History

CRSP Stock News Headlines

CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.3%
CRSP May 2024 39.000 put
Is CRISPR Therapeutics Stock a Buy?
The 3 Best Cathie Wood Stocks to Buy in May 2024
See More Headlines
Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
17 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$371.21 million
Book Value
$23.70 per share


Free Float
Market Cap
$4.71 billion
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Rodger Novak M.D. (Age 55)
    Founder, Chairman & Pres
  • Dr. Samarth  KulkarniDr. Samarth Kulkarni (Age 43)
    CEO & Director
    Comp: $1.18M
  • Dr. Lawrence Otto Klein Ph.D. (Age 40)
    Chief Operating Officer
    Comp: $675k
  • Mr. James R. KasingerMr. James R. Kasinger (Age 50)
    Gen. Counsel & Sec.
    Comp: $648.93k
  • Mr. Shaun Foy
  • Dr. Emmanuelle Marie Charpentier
    Co-Founder & Scientific Advisory Board Member
  • Dr. Craig C. Mello Ph.D.
    Scientific Founder & Advisory Board Member
  • Dr. Chad Cowan Ph.D.
    Scientific Founder
  • Dr. Matthew Porteus M.D. (Age 56)
    Ph.D., Scientific Founder & Advisory Board Member
  • Dr. Daniel G. Anderson Ph.D.
    Scientific Founder & Advisory Board Member

CRSP Stock Analysis - Frequently Asked Questions

Should I buy or sell CRISPR Therapeutics stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 2 sell ratings, 7 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CRSP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRSP, but not buy additional shares or sell existing shares.
View CRSP analyst ratings
or view top-rated stocks.

What is CRISPR Therapeutics' stock price target for 2024?

17 brokerages have issued 1 year target prices for CRISPR Therapeutics' stock. Their CRSP share price targets range from $30.00 to $112.00. On average, they expect the company's share price to reach $73.93 in the next twelve months. This suggests a possible upside of 33.3% from the stock's current price.
View analysts price targets for CRSP
or view top-rated stocks among Wall Street analysts.

How have CRSP shares performed in 2024?

CRISPR Therapeutics' stock was trading at $62.60 at the beginning of the year. Since then, CRSP shares have decreased by 11.4% and is now trading at $55.47.
View the best growth stocks for 2024 here

When is CRISPR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our CRSP earnings forecast

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) posted its quarterly earnings results on Wednesday, May, 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by $0.08. The firm earned $0.50 million during the quarter, compared to analysts' expectations of $25.53 million. The business's revenue was down 99.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.67) earnings per share.

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

CRISPR Therapeutics (CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Capital International Investors (9.23%), Sumitomo Mitsui Trust Holdings Inc. (3.85%), Nikko Asset Management Americas Inc. (3.85%), Vanguard Group Inc. (1.93%), SR One Capital Management LP (1.24%) and Bellevue Group AG (0.73%). Insiders that own company stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Michael John Tomsicek, Raju Prasad, Rodger Novak and Samarth Kulkarni.
View institutional ownership trends

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRSP) was last updated on 5/21/2024 by Staff

From Our Partners